Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

Taku Fujimura; Kayo Tanita; Yota Sato; Yumi Kambayashi; Sadanori Furudate; Akira Tsukada; Akira Hashimoto; Setsuya Aiba

doi:10.1159/000486278

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

Taku Fujimura, Kayo Tanita, Yota Sato, Yumi Kambayashi, Sadanori Furudate, Akira Tsukada, Akira Hashimoto, Setsuya Aiba

Tohoku University

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

Original language	English
Pages (from-to)	29-32
Number of pages	4
Journal	Case Reports in Oncology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1159/000486278
Publication status	Published - 2018 Jan 19

Keywords

Erythrodermic mycosis fungoides
Etoposide
Mogamulizumab

Access to Document

10.1159/000486278

Cite this

@article{37bbdb1af90841d99a1142bb566d9798,

title = "Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy",

abstract = "Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in S{\'e}zary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.",

keywords = "Erythrodermic mycosis fungoides, Etoposide, Mogamulizumab",

author = "Taku Fujimura and Kayo Tanita and Yota Sato and Yumi Kambayashi and Sadanori Furudate and Akira Tsukada and Akira Hashimoto and Setsuya Aiba",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s) Published by S. Karger AG, Basel.",

year = "2018",

month = jan,

day = "19",

doi = "10.1159/000486278",

language = "English",

volume = "11",

pages = "29--32",

journal = "Case Reports in Oncology",

issn = "1662-6575",

publisher = "S. Karger AG",

number = "1",

}

TY - JOUR

T1 - Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

AU - Fujimura, Taku

AU - Tanita, Kayo

AU - Sato, Yota

AU - Kambayashi, Yumi

AU - Furudate, Sadanori

AU - Tsukada, Akira

AU - Hashimoto, Akira

AU - Aiba, Setsuya

PY - 2018/1/19

Y1 - 2018/1/19

N2 - Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

AB - Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

KW - Erythrodermic mycosis fungoides

KW - Etoposide

KW - Mogamulizumab

UR - http://www.scopus.com/inward/record.url?scp=85040712852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040712852&partnerID=8YFLogxK

U2 - 10.1159/000486278

DO - 10.1159/000486278

M3 - Article

AN - SCOPUS:85040712852

SN - 1662-6575

VL - 11

SP - 29

EP - 32

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this